Safety Alerts & Recalls
Search all Safety Alerts & Recalls
Latest Alerts
Sprycel Linked To Raised Blood Pressure In The Lungs
The Food and Drug Administration (FDA) has alerted healthcare professionals that Sprycel (dasatinib) may increase the risk of a rare but serious condition called Pulmonary Arterial Hypertension (PAH). PAH is a condition of abnormally high blood pressure in the arteries of the lungs and can lead to heart failure. Symptoms of PAH may include shortness of breath, fatigue, and swelling of the body (such as the ankles and legs). In reported cases, patients developed PAH after starting Sprycel, including some cases of PAH that developed after more than one year of treatment with Sprycel.
Patients should be evaluated for signs and symptoms of heart and lung disease prior to starting Sprycel and during treatment. Information about this risk has been added to the Warnings and Precautions section of the Sprycel drug label.
Sprycel which contains the drug dasatinib is used in the treatment of certain types of leukemia in adults.
For more information please visit:
http://www.fda.gov/Drugs/DrugSafety/ucm275155.htm
Learn More
Study Links High Doses of Vitamin E to Possible Increase in Prostate Cancer Risk
A recently published study in the Journal of the American Medical Association is raising concerns about excessive use of vitamins, specifically Vitamin E. According to this large federal study, large daily doses of Vitamin E may increase the risk for prostate cancer among middle-aged men.
This study adds to the growing number studies highlighting concerns about the long-term use of high dose vitamin and mineral supplements by people who do not have severe nutritional deficiencies.
For more information, please visit:
http://jama.ama-assn.org/content/306/14/1549.short
Learn More